$HBAN

Kleinman Scott D sold $315K of HBAN

Kleinman Scott D (Senior Exec. V.P.) sold 19,425 shares of HUNTINGTON BANCSHARES INC /MD/ (HBAN) at $16.20 ($0.31M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kleinman Scott D
Published Jun 3, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 8:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HBAN
Neutral
medium confidence
Mentioned
$HBAN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HBANNeutralLow
01

Why it matters

The disclosure provides a datapoint on insider behavior but does not indicate a new fundamental event (no earnings, guidance, deal, or regulatory action).

02

Market read

Traders may note the insider sale for sentiment/positioning, but the 10b5-1 designation limits actionable inference.

03

What to watch

Insider sales can be routine and scheduled; without additional context (e.g., multiple consecutive sales, changes in plan parameters), directional inference is weak.

Relevance 6/10Novelty 6/10Timing: Filed June 3, covering a sale executed June 1

Background

SEC Form 4 reports insider transactions; this one is an officer open-market sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$HBANNeutralMedium confidence
Context

Huntington Bancshares officer Scott D. Kleinman sold 19,425 shares in an open-market transaction disclosed on Form 4.

Expected impact

Likely limited immediate price impact; any effect is more sentiment/flow-related than fundamental.

Evidence & confidence

The filing is an officer open-market sale and explicitly states a pre-arranged 10b5-1 plan, which reduces interpretability as a reaction to new information.

Market effects

Minimal; this is company-specific insider disclosure without sector-wide catalyst.

Minimal; no broader regional banking trigger indicated.

Minimal; no international or macro linkage beyond the issuer’s own trading activity.

Counterpoint

Treat the sale as potentially informative about liquidity/portfolio management rather than bearish signals, especially given the 10b5-1 structure.

Key entities

  • Huntington Bancshares Inc /MD/

    HBAN officer Scott D. Kleinman sold 19,425 shares at $16.20 on June 1, 2026 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HBANMedAI 8/10

Huntington Bancshares 3Q 2026: Revenue $2.79B, EPS $0.33— 10-Q Summary

Huntington Bancshares reported 3Q 2026 revenue of $2.79B, up 30.8% YoY, and net income of $721M, up 14.6% YoY. EPS was $0.33, down 19.5% YoY, due to acquisition-related expenses. Growth was driven by acquisitions, organic growth, and higher net interest income. Management highlighted progress in integrating recent acquisitions and investing in technology.

$SEBMed

Sweden’s SEB pauses buybacks as Barclays plans further capital returns ahead of Basel 3.1

SEB paused buybacks due to capital buffer pressure from model adjustments and loan growth, reporting a 17.1% CET1 ratio. Barclays announced a GBP 500M buyback, expecting Basel 3.1 to reduce its CET1 ratio but maintain distribution headroom. EU agreed lower capital requirements for qualifying securitisations. Huntington Bancshares saw diverging capital ratios due to interest-rate losses. BPI's provisions fell despite worsening problem-loan metrics.

$HBANMedAI 8/10

Huntington Bancshares Inc (HBAN) (Q3 2026) Earnings Call Highlights: Strong Fee Growth

Huntington Bancshares (HBAN) reported strong Q3 2026 results, with fee revenue up over 15% YoY and commercial loan growth driving a 1.1% increase in loan balances. The company expects 2027 EPS growth of over 20% and ROTCE of 17%-18%. However, it faces challenges like a competitive environment and slightly lowered fee revenue guidance for Q4. The bank repurchased $460 million in stock YTD and plans $1.8-$1.9 billion in buybacks for 2026-2027.

$HBANHighAI 8/10

Huntington Bancshares Inc (HBAN) (Q3 2026) Earnings Call Highlig

Huntington Bancshares (HBAN) reported Q3 2026 earnings with net interest income up 0.9% quarter-over-quarter and 37% year-over-year. Net interest margin increased 4 basis points to 3.25%. Non-interest expense remained flat, while value-added fee revenue rose over 15% year-over-year. Loans grew 1.1% period-end, and deposits increased 0.2%. The company expects 2027 EPS growth of over 20% and plans $1.8-$1.9 billion in share repurchases through 2027.

$HBANMed

Huntington (HBAN) Q3 2026 Earnings Call Transcript

Huntington (HBAN) reported strong Q3 2026 earnings, with C&I growth driven by national commercial strategy. The company expects 2027 EPS to grow over 20% from 2025, with ROTCE in the 17-18% range. They have completed $460 million in share repurchases year-to-date and plan to return substantial capital to shareholders. Huntington's operating model combines local and national commercial banking, with $191 billion in loans and $225 billion in deposits.

$HBANMed

What Huntington Bancshares (HBAN) Said on Its Q3 Earnings Call

Huntington Bancshares (HBAN) reported Q3 earnings with net interest income at $2.1B, up 0.9% sequentially. Net interest margin increased to 3.25%, with management expecting it to remain flat in Q4. Fee revenue grew 15% YoY, and noninterest expense was stable. The company repurchased $460M of common stock YTD and expects $1.8B-$1.9B in repurchases over 2023-2024. Net charge-offs were 31 basis points, with stable credit performance.